Targeted Genetics will have five clinical trial programs following Rgene Therapeutics acquisition.
TARGETED GENETICS WILL HAVE FIVE CLINICAL PROGRAMS AFTER RGENE ACQUISITION announced April 16. Acquisition of The Woodlands, Tex.-based Rgene Therapeutics gives Targeted Genetics the rights to its proprietary non-viral gene delivery technology and the E1A tumor suppression gene complexed with DC-cholesterol (RGG-0853), which has received orphan drug designation for advanced ovarian cancer and is now in Phase I trials for ovarian and breast cancer treatment.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth